Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2007

The neuroendocrine impact of chronic stress on cancer
Premal H. Thaker
Washington University School of Medicine in St. Louis

Susan K. Lutgendorf
University of Iowa

Anil K. Sood
University of Texas M.D. Anderson Cancer Center

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Thaker, Premal H.; Lutgendorf, Susan K.; and Sood, Anil K., ,"The neuroendocrine impact of chronic stress
on cancer." Cell Cycle. 6,4. 430-433. (2007).
https://digitalcommons.wustl.edu/open_access_pubs/3030

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

[Cell Cycle 6:4, 430-433, 15 February 2007]; ©2007 Landes Bioscience

Perspective

The Neuroendocrine Impact of Chronic Stress on Cancer
Abstract
Behavioral processes have long been suspected to influence many health processes
including effects on cancer. However, mechanisms underlying these observations are not
fully understood. Recent work has demonstrated that chronic behavioral stress results in
higher levels of tissue catecholamines, greater tumor burden, and a more invasive pattern
of ovarian cancer growth in an orthotopic mouse model. These effects are mediated
primarily through the b2 adrenergic receptor (ADRB2) activation of the tumor cell cyclic
AMP (cAMP)‑protein kinase A (PKA) signaling pathway. Additionally, tumors in stressed
animals have increased vascularization and enhanced expression of vascular endothelial
growth factor (VEGF) and matrix metalloproteinases (MMPs) ‑2 and ‑9. In this review,
we highlight the importance of the neuroendocrine stress response in tumor biology and
discuss mechanisms by which the b‑adrenergic receptors on ovarian cancer cells enhance
angiogenesis and tumor growth.
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Over twenty-five years ago, Engel recognized that biological factors alone cannot account
for all changes in physical health and that social and behavioral dimensions must also be
considered.1 In clinical and epidemiological studies, cancer progression, and to a lesser
extent, cancer onset have been related to chronic stress, depression, lack of social support
and other psychological factors.2‑6 Stress is a complex process encompassing environmental
and psychosocial factors and initiates a cascade of information‑processing pathways in both
the central and peripheral nervous systems. Ultimately, the fight‑or‑flight stress responses
in the autonomic nervous system (ANS) or the defeat/withdrawal responses in the
hypothalamic‑pituitary‑adrenal axis (HPA) are generated and secrete catecholamines and
cortisol, respectively (Fig. 1).7,8 Activation of these pathways in acute stress are necessary
for survival and are adaptive processes. In contrast, chronic stress negatively affects most
physiological systems due to prolonged exposure to catecholamines and glucocorticoids.9
Chronic stress has been shown to decrease cellular immune parameters, such as natural
killer (NK) cell cytotoxicity and T‑cell responses to mitogen stimulation.10‑12 Effects
of biobehavioral factors on the immune system are thought to be mediated in part by
the sympathetic nervous system, the HPA axis, and a variety of other hormones and
peptides.13,14 To date, the majority of neuroendocrinological research dealing with stress
and accelerated tumor growth has focused on suppressed immune response to malignant
tissue.7 Recently, we and others have considered other biological pathways that may be
affected by stress mediators. These observations are the focus of the current review.

.D

Previously published online as a Cell Cycle E-publication:
http://www.landesbioscience.com/journals/cc/abstract.php?id=3829

Key words

IEN

CE

angiogenesis, carcinoma, stress
Acknowledgements

©

20

07

LA

ND

ES

BIO

SC

This research was supported in part by U.S.
NIH grants CA11079301 and CA10929801,
The University of Texas MD Anderson
Cancer Center Spore in Ovarian Cancer
(2P50CA083639), and a Program Project
Development Grant from the Ovarian Cancer
Research Fund, Inc. to A.K.S., and NIH grant
CA104825 to S.K.L.

430

Neuroendocrine Influences on Cancer
Tumorigenesis is a multistep process, and according to Hanahan and Weinberg, there
are six essential acquired alterations in cell physiology that promote malignant growth: (1)
self‑sufficiency in growth signals, (2) insensitivity to anti‑growth signals, (3) evasion of
apoptosis, (4) limitless replicative potential, (5) sustained angiogenesis and (6) tissue invasion and metastasis.15 After a cell acquires tumorigenic potential, then cancer metastasis can
occur if another series of sequential interrelated steps including proliferation/angiogenesis,
invasion, embolism/circulation, transport, adherence in organs, adherence to vessel wall
and extravasation occur.16 Tumor progression is a result of crosstalk between different cell
types within the tumor and its surrounding supporting tissue, tumor stroma and microenvironment.17 Emerging research is now beginning to explore the role of neuropeptides
Cell Cycle
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Figure 1. Key components of the central and peripheral stress systems. In
response to neurosensory signals, the hypothalamus secretes corticotro‑
phin‑releasing factor (CRF) and arginine vasopressin (AVP), which cause
the pituitary to secrete adrenocorticotropic hormone (ACTH). Subsequently,
ACTH promotes the production of glucocorticoids from the adrenal cortex.
The sympathetic nervous system originates in the brain stem, and ultimately
through post‑ganglionic fibers releases noradrenaline. The adrenal medulla
releases mainly adrenaline. Reprinted with permission from Nature Reviews
Cancer (see ref. 8).
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rine can enhance the invasive potential of ovarian carcinoma cells
via the ADRB‑mediated increases in matrix metalloproteinases
(MMPs). The b‑adrenergic antagonist propranolol and pharmacologic blockade of MMPs abrogated the effects of norepinephrine on
the increases in tumor cell invasive potential.30 This work provided
the in vitro evidence that stress hormones can increase the invasive
potential of ovarian cancer cells.
Avoidance of apoptosis is a critical component of the metastatic
cascade. Thus far, glucocorticoids, which regulate a variety of cellular
processes, have been the focus of research elucidating the role of
stress hormones on tumor cell survival. Glucocorticoids downregulate
proapoptotic elements of the death receptor and mitochondrial
apoptosis pathways in cervical and lung cancer cell lines.31 Wu and
colleagues found that breast cancer cell lines pretreated with dexamethasone inhibited chemotherapy‑induced apoptosis via transcriptional
induction of serum and GC‑inducible protein kinase‑1 (SGK‑1) and
mitogen activated protein kinase phosphatase‑1 (MKP‑1).32 The
antiapoptotic effects of glucocorticoid treatment could be reversed by
blockade of SGK‑1 and MKP‑1.32 Additionally, glucocorticoids and
catecholamines may act synergistically to facilitate cancer growth as
evidenced in lung carcinoma cell lines.33
Angiogenesis is a key process in the growth of most solid tumors
beyond 1–2 mm in diameter, and their metastatic spread involves
recruitment of nearby blood vessels to permeate the tumor.34 In
vascular endothelial cells, ischemic neoangiogenesis causes proliferation via overexpression of the ADRB.35 Vascular endothelial growth
factor (VEGF) is a key proangiogenic cytokine that is produced by
tumor cells, endothelial cells, and platelets.36 We have previously
reported that higher levels of social support were correlated with
lower VEGF levels in serum from presurgical patients with ovarian
carcinoma providing a possible mechanism by which poor social
support may be associated with disease progression.37 We have also
demonstrated that VEGF production by ovarian cancer cell lines
was enhanced by stress hormones such as norepinephrine, epinephrine, and isoproterenol in vitro and blocked by the b‑antagonist
propranolol.38 Based on our previous studies, we sought to elucidate
whether chronic stress and the associated increase in sympathetic
nervous system activity had a causal effect on growth and metastasis
of ovarian cancer in vivo.39
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and neurotransmitters, which are increased in certain biobehavioral
states on the multistep process of cancer metastasis.
In order to proliferate, tumor cells rely on nutrient and oxygen
diffusion. The effects of stress‑related hormones on tumor cell proliferation can be either stimulatory or inhibitory depending on the
type of hormone and tumor type. For example, in breast carcinoma,
activation of b‑adrenergic receptors (ADRB) has been associated
with accelerated tumor growth.18‑20 In contrast, catecholamines may
inhibit tumor cell proliferation that may be mediated by a‑adrenergic
receptors or the dopamine transporter. Scarparo and colleagues
found that melanoma cells treated with the a1‑adrenergic agonist
phenylephrine led to a dose‑dependent decrease in proliferation,
which could be reversed by the a1‑adrenergic antagonist prazosin.21
Additionally, norepinephrine treatment shifted neuroblastoma cells
expressing the dopamine transporter into the G0/G1 phase, thereby
inhibiting proliferation.22 Similarly, the role of glucocorticoid
hormones on proliferation is dual.23,24
The ability of a tumor cell to invade and metastasize to distant
tissues is highly dependent on malignant cell adhesion to the extracellular matrix.25 Enserink and colleagues have shown that the
b‑agonist isoproterenol promotes ovarian cancer cell spreading and
adhesion via integrins through Epac (exchange factor directly activated by cAMP)‑Rap1 pathway.26,27 Additionally, there is growing
evidence that stress hormones may affect tumor cell motility and
invasion. Norepinephrine has been shown to induce breast and
colon cancer migration.28,29 We have previously demonstrated that
physiologic stress concentrations of norepinephrine and epinephwww.landesbioscience.com

The Role of Chronic Stress on Tumor Growth
and Angiogenesis in Orthotopic Ovarian Carcinoma
We recently demonstrated that chronic stress (daily restraint)
quantitated by elevated organ catecholamine (norepinephrine and
cortisol) levels enhanced the pathogenesis of ovarian carcinoma
in vivo, as evidenced by increased tumor weight and more invasive
pattern of metastasis including parenchymal liver, spleen, and
diaphragm involvement. Propranolol, a non-specific b‑blocker,
completely blocked the effects of immobilization stress on tumor
growth, indicating a critical role for b‑adrenergic signaling in stress
mediated increases in tumor growth. The b‑adrenergic receptors are
G‑protein‑coupled receptors that mainly function to transmit extracellular information to the interior of the cell, causing an activation of
adenylyl cyclase and an accumulation of the second messenger cAMP
to activate the protein kinase A pathway.40 Ultimately, after catecholamine stimulation, the activation of the tumor cell cAMP‑protein
kinase A signaling pathway led to increased VEGF gene expression,
resulting in increased tumor vascularization and more aggressive
growth. A series of experiments using either ADRB‑null cell lines,
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VEGF‑mediated angiogenesis in vivo (Fig. 2), and underscores the
importance of the neuroendocrine system in cancer pathogenesis.

Clinical Opportunities and Challenges
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The knowledge of how stress biology affects tumor initiation and
pathogenesis is gradually expanding. Biobehavioral factors such as
chronic stress, depression, and social support have been linked to
tumor biology via their endocrine consequences and cell mediated
immunity. Although the molecular pathways have not been fully
elucidated, the studies to date indicate possible opportunities for
behavioral and pharmacological intervention that target tumor‑supporting neuroendocrine dynamics.
Pharmacologic and genetic manipulations identify b‑adrenergic
signaling as a central mediator of stress effects on cancer growth;
therefore, pharmacological interventions such as b‑blockers potentially could be used to alleviate the effects of stress on cancer growth
and progression. Interestingly, in a large case‑control study of prostate
cancer patients, Perron and colleagues found that among individuals
taking anti‑hypertensive medications, only b‑blockers were associated
with a reduction in cancer risk.41 A cohort study of cardiovascular
patients that used b‑blockers had a 49% decrease in cancer risk
compared to patients that never used b‑blockers. Moreover, there
was a 6% decrease in risk for every additional year of b‑blocker
use.42 However, other population‑based case‑control studies of breast
carcinoma patients have not confirmed alterations in risk with the
use of b‑blockers.43,44 The efficacy of b‑blockers in blocking the
stress‑mediated effects on tumor remains to be examined.
To the extent that behavioral and central nervous system processes
modulate the activity of multiple hormones45‑48 and those processes are
linked to angiogenic parameters in human clinical studies37,49 interventions targeting neuroendocrine function at the CNS level might
also represent novel strategies for protecting cancer patients from the
detrimental effects of stress biology on the progression of malignant
disease. Such interventions may include behavioral interventions
alone or in combination with pharmacological approaches.8
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pharmacological b‑agonists, or ADRB‑silencing with siRNA, demonstrated that ADRB2 on the tumor cells plays a functionally significant
role in stress‑mediated angiogenesis. The increased angiogenesis
occurred in response to increases in catecholamine induced VEGF
production by tumor cells. The tumor vasculature in stressed animals
contained more tortuous and numerous blood vessels than controls,
and was accompanied by a significant decrease in the proportion of
blood vessels with pericyte coverage in tumors from stressed animals,
which suggests more immature vasculature. Additionally, magnetic
resonance imaging and kinetic analysis of the stressed tumors showed
substantial anatomical and functional alterations in tumor vasculature.
Both propranolol and VEGF blocker such as the VEGF‑R2
inhibitor PTK787 or the monoclonal VEGF‑specific antibody
bevacizumab completely blocked the stress induced effects on tumor
burden and invasiveness. These results demonstrated that behavioral
stressors can enhance the pathogenesis of ovarian carcinoma via
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Figure 2. Effects of stress on ovarian cancer growth via VEGF‑mediated
angiogenesis. Chronic stress leads to the activation of the autonomic nervous
system (ANS) and the hypothalamic‑pituitary‑adrenal (HPA) axis, which result
in release of catecholamines such as norepinephrine and epinephrine. These
catecholamines then activate the b‑adrenergic receptors on ovarian cancer
cells to secrete VEGF and other angiogenic factors, leading to enhanced
tumor growth and increased vascularity. Reprinted and modified with permis‑
sion from Nature Reviews Cancer (see ref. 8).
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Although research has shown that stress hormones affect tumor
pathogenesis at multiple levels (initiation, tumor growth, and metastasis), our understanding of the underlying mechanisms is in its
infancy and needs to be expanded. Based on the importance of the
interplay between immunological and behavioral factors providing
a favorable microenvironment for tumor initiation and growth,
there is a crucial need to integrate a bio‑behavioral perspective in
therapeutic paradigms of human carcinoma. Interventions targeting
neuroendocrine function at the level of the central nervous system
could represent a novel strategy for protecting cancer patients
from the deleterious effects of stress biology on cancer progression.
Theoretically, these pharmacologic and behavioral interventions can
be used concomitantly with conventional therapies to maximize efficacy and warrant further study, especially as cancer treatment evolves
to encompass more patient‑specific therapeutic approaches.
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